Who owns Ultragenyx Pharmaceutical Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of RARE from SEC Form 13F filings across 310 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 310 institutions disclosed 106.3M shares of Ultragenyx Pharmaceutical Inc. worth $3.54B — about 104.3% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
310
13F holders
$3.54B
value, 2026 filers
104.3%
of shares outstanding (106.3M sh)
61
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of RARE's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 10.7M | $355.7M | 0.0% | 10.5% | +46.0% |
| 2 | RTW INVESTMENTS, LP | 7.8M | $260.3M | 2.2% | 7.7% | +113.7% |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.8M | $226.7M | 0.0% | 6.7% | +26.1% |
| 4 | AQR CAPITAL MANAGEMENT LLC | 6.6M | $214.1M | 0.1% | 6.4% | +43.3% |
| 5 | STATE STREET CORP | 6.2M | $205.6M | 0.0% | 6% | +22.6% |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 4.3M | $143.5M | 0.0% | 4.2% | +2.5% |
| 7 | TWO SIGMA INVESTMENTS, LP | 3.6M | $120.9M | 0.1% | 3.6% | +64.2% |
| 8 | SANDS CAPITAL MANAGEMENT, LLC | 3.2M | $105.5M | 0.4% | 3.1% | -1.7% |
| 9 | JACOBS LEVY EQUITY MANAGEMENT, INC | 2.9M | $98.2M | 0.4% | 2.9% | +105.4% |
| 10 | FRONTIER CAPITAL MANAGEMENT CO LLC | 2.8M | $95.1M | 0.9% | 2.8% | +30.0% |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 2.6M | $86.1M | 0.0% | 2.5% | +39.4% |
| 12 | Bellevue Group AG | 2.0M | $66.2M | 1.4% | 1.9% | -16.7% |
| 13 | D. E. Shaw & Co., Inc. | 1.7M | $57.8M | 0.0% | 1.7% | +37.2% |
| 14 | Sofinnova Investments, Inc. | 1.7M | $57.3M | 3.0% | 1.7% | -45.4% |
| 15 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.6M | $52.8M | 0.1% | 1.6% | +229.2% |
| 16 | GW&K Investment Management, LLC | 1.5M | $49.5M | 0.4% | 1.5% | -8.3% |
| 17 | MPM BIOIMPACT LLCNEW | 1.4M | $47.4M | 2.9% | 1.4% | new |
| 18 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.4M | $45.3M | 0.0% | 1.3% | +68.7% |
| 19 | MORGAN STANLEY | 1.3M | $44.2M | 0.0% | 1.3% | -11.7% |
| 20 | WELLINGTON MANAGEMENT GROUP LLP | 1.3M | $41.8M | 0.0% | 1.2% | -52.6% |
| 21 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 1.2M | $41.5M | 0.2% | 1.2% | -13.0% |
| 22 | BANK OF AMERICA CORP /DE/ | 1.1M | $38.3M | 0.0% | 1.1% | +9.7% |
| 23 | Candriam S.C.A. | 1.0M | $33.4M | 0.2% | 1% | -8.6% |
| 24 | Rock Springs Capital Management LP | 967,855 | $32.3M | 1.6% | 0.9% | -20.6% |
| 25 | Jefferies Financial Group Inc. | 929,626 | $31.0M | 0.2% | 0.9% | +5902.2% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.